- 17Jul, 2026
This article was originally published on drugdiscoveryonline.com. By Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals For decades, sexually transmitted infections (STIs), such as gonorrhea and chlamydia, were viewed as straightforward to treat. A single injection or short oral course of antibiotics was typically sufficient. [...]
Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance
Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.
Turning the Tide: Innovations in the Fight Against Super Gonorrhea
As we navigate the complexities of modern medicine, a quiet threat remains: multi-drug resistant gonorrhea (MDRSG, commonly referred to as Super Gonorrhea), a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae. Super gonorrhea is a prime example of how bacteria can outsmart our best defenses. At TAXIS, we are diving headfirst into the science of combating antimicrobial AMR.
Contagion Live: A Group of Antimicrobial Compounds Shows Novelty Action Against Multidrug-Resistant Gonorrhea
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae, a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae.
- 15Jul, 2025
TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors.
- 15Jul, 2025
A conversation with Gregory G. Mario and Ajit K. Parhi, Ph.D., TAXIS Pharmaceuticals originally published in Drug Discovery Online.
- 15Jul, 2025
TAXIS has received a $2.9 million grant to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea, a rapidly spreading deadly and highly resistant strain of Neisseria gonorrhoeae.
